T2	eligibility 267 318	women at high risk for development of breast cancer
T3	control 819 826	placebo
T4	outcome-Measure 928 960	improvement in cytologic pattern
T5	total-participants 965 968	119
T8	outcome 1096 1118	total urine polyamines
T1	intervention 55 84	alpha-difluoromethylornithine
T13	outcome 1168 1210	reduction in the spermidine:spermine ratio
T9	outcome 1239 1260	cytologic improvement
T10	outcome 1378 1409	breast molecular marker changes
T14	outcome 1524 1551	mammographic breast density
T15	outcome 1553 1587	serum insulin-like growth factor I
T16	outcome 1641 1655	adverse events
T17	outcome 1657 1680	quality of life indices
T18	outcome 1685 1714	subsequent cancer development
